{"anticipatedPostingDate":"2026-09","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"From the date of first dose up to 37 months","title":"Percentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against Elranatamab","type":"SECONDARY"}